* subjects who are participating in another clinical trial. * subjects who are unable to offer cooperation and/or have serious psychiatric disorders. * subjects who are allergic to any of the compounds included into mv130. * subjects who present contraindications to any of the components of bacmune (mv130). * subjects who are not able to comply with the dosage regimen. * subjects with immunodeficiencies. * subjects with malignancy involving the bone marrow or lymphoid systems. * pregnant or suspected pregnant women and breastfeeding women. * subjects in medical treatment that affects the response of the immune system. it includes corticosteroids (equal to or more than 20 mg for more than 2 weeks), immunosuppressants, biological agents (such as anti tnf-alpha monoclonal antibodies, etc.). * subjects with hiv. * subjects under treatment with metformin. * subjects treated with sertraline. * subjects treated with statins.

* subjects who are participating in another clinical trial. * subjects who are unable to offer cooperation and/or have serious psychiatric disorders. * subjects who are allergic to any of the compounds included into mv130. * subjects who present contraindications to any of the components of bacmune (mv130). * subjects who are not able to comply with the dosage regimen. * subjects with immunodeficiencies. * subjects with malignancy involving the bone marrow or lymphoid systems. * pregnant or suspected pregnant women and breastfeeding women. * subjects in medical treatment that affects the response of the immune system. it includes corticosteroids (equal to or more than 20 mg for more than 2 weeks), immunosuppressants, biological agents (such as anti tnf-alpha monoclonal antibodies, etc.). * subjects with hiv. * subjects under treatment with metformin. * subjects treated with sertraline. * subjects treated with statins.

- subjects who are participating in another clinical trial. - subjects who are unable to offer cooperation and/or have serious psychiatric disorders. - subjects who are allergic to any of the compounds included into mv130. - subjects who present contraindications to any of the components of bacmune (mv130). - subjects who are not able to comply with the dosage regimen. - subjects with immunodeficiencies. - subjects with malignancy involving the bone marrow or lymphoid systems. - pregnant or suspected pregnant women and breastfeeding women. - subjects in medical treatment that affects the response of the immune system. it includes corticosteroids (equal to or more than 20 mg for more than 2 weeks), immunosuppressants, biological agents (such as anti tnf-alpha monoclonal antibodies, etc.). - subjects with hiv. - subjects under treatment with metformin. - subjects treated with sertraline. - subjects treated with statins.

- subjects who are participating in another clinical trial. - subjects who are unable to offer cooperation and/or have serious psychiatric disorders. - subjects who are allergic to any of the compounds included into mv130. - subjects who present contraindications to any of the components of bacmune (mv130). - subjects who are not able to comply with the dosage regimen. - subjects with immunodeficiencies. - subjects with malignancy involving the bone marrow or lymphoid systems. - pregnant or suspected pregnant women and breastfeeding women. - subjects in medical treatment that affects the response of the immune system. it includes corticosteroids (equal to or more than 20 mg for more than 2 weeks), immunosuppressants, biological agents (such as anti tnf-alpha monoclonal antibodies, etc.). - subjects with hiv. - subjects under treatment with metformin. - subjects treated with sertraline. - subjects treated with statins.